Survey on resistance of clinical isolates of Gram-negative bacteria in 2002

Chinese Journal of Antibiotics

Volumn 29, Issue 9, 2004, Pages 549-555

  Ma, Yue ^a   Li, Jing Yun ^a   Zhang, Xin Mei ^a   Xu, Ming Zhe ^a   Zou, Wen Bo ^a   Hu, Chang Qin ^a   Jin, Shao Hong ^a  

^a NATIONAL INSTITUTE FOR THE CONTROL OF PHARMACEUTICAL AND BIOLOGICAL PRODUCTS   (China)

Author keywords

Antimicrobial resistance; Disc diffusion method; Gram negative bacteria; Surveillance

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZTREONAM; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEFACLOR; CEFAZOLIN; CEFEPIME; CEFOPERAZONE; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; NALIDIXIC ACID; NITROFURANTOIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; SULPERAZON; SULTAMICILLIN; TIMENTIN; UNINDEXED DRUG;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ARTICLE; CITROBACTER; CONTROLLED STUDY; DIFFUSION; ENTEROBACTER; ENTEROBACTERIACEAE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; KLEBSIELLA PNEUMONIAE; NONHUMAN; PROVIDENCIA; PSEUDOMONAS AERUGINOSA; SALMONELLA; SECRETION; SERRATIA; SPUTUM; URINE; WOUND;

EID: 9644308092     PISSN: 10018689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Jenkins P. WHO global strategy for containment for antimicrobial resistance [R]. WHO, General, 2001:1
2. Murray P R, Baron E J, Pfaller M A, et al. Manual of Clinical Microbiology [M]. 7th ed. American Society for Microbiology, Washington, D. C. 1999:262
3. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing [S]. 12th inform suppl. M2-A7 and M7-A5. National Committee for Clinical Laboratory Standards, Wayne, pa, 2002:34
4. Pfaller M A, Jones R N. For the MYSTIC study group. MYSTIC (meropenem yearly susceptibility test information collection) results from the Americas: resistance implications in the treatment of serious infections [J]. J Antimicrob Chemother, 2000,46:25
5. Jean S S, Teng L J, Hsueh P R, et al. Antimicrobial susceptibilities among clinical isolates of extended-spectrum cephalosporin-resistant Gram-negative bacteria in a Taiwanese university hospital [J]. J Antimicrob Chemother, 2002,49:69
6. Wang H, Wu W Y, Chen M J. Study of clinical isolates of Enterobacteriaceae producing extended-spectrum β-lactamase [J]. Chin J Microbiol Immunol, 2001,21:676
7. She D Y, Liu Y N. The expression of AmpC and extended-spectrum β-lactamase among clinical isolates of Enterobacter cloacae and impact on antibiotics susceptibility [J]. Nal Med J China, 2002,82:1351
8. Ma Y, Chen H B, Li J Y, et al. Trend of antimicrobial resistance in Salmonella species during 1998-2000 [J]. Chin J Infect Chemother, 2002,2:284
9. Senda K, Arakawa Y, Nakashima K, et al. Multifocal outbreaks of metallo-β-lactamase producing Pseudomonas aeruginosa resistance to broad-spectrum β-lactam, including carbapenems [J]. Antimicrob Agents Chemother, 1996,40:349
10. Bonfiglio G, Laksai Y, Granchino L, et al. Mechanisms of β-lactam resistance amongst Pseudomonas aeruginosa isolated in an Italian survey [J]. J Antimicrob Chemother, 1998:42(5):697